EE470 Zanubrutinib Versus Ibrutinib to Treat Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Cost Per Responder Model From a Payer Perspective in the United States
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.715
https://www.valueinhealthjournal.com/article/S1098-3015(22)02919-9/fulltext
Title :
EE470 Zanubrutinib Versus Ibrutinib to Treat Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Cost Per Responder Model From a Payer Perspective in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02919-9&doi=10.1016/j.jval.2022.09.715
First page :
Section Title :
Open access? :
No
Section Order :
10252